Indirubin-3'-monoxime

TargetMol
Product Code: TAR-T5200
Supplier: TargetMol
CodeSizePrice
TAR-T5200-1mg1mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5200-5mg5mg£120.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5200-1mL1 mL * 10 mM (in DMSO)£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5200-10mg10mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5200-25mg25mg£241.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5200-50mg50mg£373.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5200-100mg100mg£536.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Indirubin-3'-oxime is a potent inhibitor of GSK3β (IC50: 22 nM) and also inhibits CDKs ( (IC50s: 100/180/250 nM for Cdk5/p35, Cdk1/cyclin B, Cdk2/cyclin E).
CAS:
160807-49-8
Formula:
C16H11N3O2
Molecular Weight:
277.283
Pathway:
Cell Cycle/Checkpoint; Stem Cells; PI3K/Akt/mTOR signaling; Metabolism
Purity:
0.9965
SMILES:
ON=C1C(Nc2ccccc12)=C1C(=O)Nc2ccccc12
Target:
GSK-3; Lipoxygenase; CDK

References

Leclerc S, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem. 2001 Jan 5;276(1):251-60. Sharma S, et al. Neuroprotective role of Indirubin-3'-monoxime, a GSK? inhibitor in high fat diet induced cognitive impairment in mice. Biochem Biophys Res Commun. 2014 Oct 3;452(4):12009-15. Damiens E, et al. Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest. Oncogene. 2001 Jun 28;20(29):3786-97. Blazevic T, et al. Indirubin-3'-monoxime exerts a dual mode of inhibition towards leukotriene-mediated vascular smooth muscle cell migration. Cardiovasc Res. 2014 Mar 1;101(3):522-32.